Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Expanded eligibility boosts U.S. COVID-19 booster shots ahead of holidays

Published 11/25/2021, 08:03 AM
Updated 11/25/2021, 07:40 PM
© Reuters. FILE PHOTO: Vials labelled "Moderna, Johnson & Johnson, Pfizer-BioNTech coronavirus disease (COVID-19) vaccine" are seen in this illustration picture taken May 2, 2021. REUTERS/Dado Ruvic

By Michael Erman and Ahmed Aboulenein

(Reuters) - Millions of Americans got COVID-19 booster shots at a near record pace after the Biden administration expanded eligibility last week, but health officials concerned about climbing infections ahead of the winter holiday season urged more to get the additional protection.

About 37.5 million people had received a booster shot in the United States as of Tuesday, according to data from the U.S. Centers for Disease Control and Prevention (CDC).

"I think it is a good start," said Dr. William Schaffner, a leading infectious disease expert from Vanderbilt University School of Medicine, who added that he believed boosters are more important for personal protection than for curtailing spread of the virus.

"I am hoping for much better. I would like to see all of that doubled very, very quickly," he said of booster uptake.

U.S. regulators expanded eligibility for vaccine booster shots to all adults, allowing millions more Americans to get additional the protection amid a recent rise in infections, including among the fully vaccinated.

Previously, people age 65 and older and those at high risk of infection due to underlying health or employment conditions were eligible for the extra shots.

Just over six million people got an additional dose of one of the three approved COVID-19 vaccines last week, CDC data shows, the highest weekly total since boosters were first authorized, and an increase of over 15% from the previous week.

Over 130 million fully vaccinated adults in the United States are now eligible for the shots, at least six months after the second dose of the Pfizer/BioNTech or Moderna (NASDAQ:MRNA) vaccines or two months after receiving Johnson & Johnson (NYSE:JNJ)'s one-dose vaccine.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

More than a quarter of those now eligible have received boosters. Some experts felt previous booster shot eligibility requirements were too complicated and may have discouraged people from getting them, or that previous evidence for the extra shots was lacking.

"There is much better justification for boosters now than when the White House first promoted the idea (in August). They did create some mixed messages," said Dr. William Moss, executive director of the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health. "We are in a better place now."

WANING IMMUNITY

Public officials, including CDC Director Rochelle Walensky and top infection disease expert Dr. Anthony Fauci, have for weeks been urging more Americans to opt for additional protection as they prepare to travel and gather with friends and family for this week's U.S. Thanksgiving holiday.

After about two months of declining infections, the United States has reported daily increases for the past two weeks, driven by the more easily transmitted Delta variant of the virus and people spending more time indoors due to colder weather.

"We'd like to get as many people who were originally vaccinated with the first regimen boosted," Fauci said https://www.reuters.com/business/healthcare-pharmaceuticals/fauci-says-vast-majority-vaccinated-americans-should-get-covid-19-booster-2021-11-23 on Tuesday in an interview for the upcoming Reuters Next conference.

He said the "overwhelming majority" of Americans who have been fully vaccinated should now receive a COVID-19 booster shot based on data showing they provide "substantial" protection beyond what is seen from the original inoculation.

Regulators backed the additional doses out of concerns over data showing immunity generated by the first shots wanes over time. Studies have shown that booster doses generate higher neutralizing antibody levels on average than the initial inoculations, and data from Pfizer (NYSE:PFE) suggests they can significantly reduce infections.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Some scientists believe boosters are unnecessary for many healthy adults, arguing that vaccinating the unvaccinated should be the priority.

The World Health Organization (WHO) has advised against countries making boosters available until more people around the world have received their primary doses.

But on Tuesday, the WHO's Regional Director for Europe, Hans Kluge, urged Europeans to get booster doses if offered in the face of surging cases. The WHO said there could be a further 700,000 deaths by March if action is not taken.

Latest comments

hello
expanded eligibility with zero liability even as the VAX injuries continues growing
Garbage! Signed the unvaxed
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.